Format

Send to

Choose Destination
Methods Mol Biol. 2016;1406:61-70. doi: 10.1007/978-1-4939-3444-7_5.

Evaluation of Human Epidermal Growth Factor Receptor 2 (HER2) Gene Status in Human Breast Cancer Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens by Fluorescence In Situ Hybridization (FISH).

Author information

1
Department of Molecular Pathology, PhenoPath Laboratories, 551 North 34th Street, Seattle, WA, 98103-8675, USA. hhwang@phenopath.com.
2
Department of Molecular Pathology, PhenoPath Laboratories, 551 North 34th Street, Seattle, WA, 98103-8675, USA.

Abstract

Current standard of care requires that HER2 gene testing be performed on all newly diagnosed invasive breast cancers in order to determine eligibility for anti-HER2 antibody therapy and should be performed in accordance with current ASCO-CAP guidelines (Hammond et al., J Clin Oncol 29(15):e458, 2011; Wolff et al., J Clin Oncol 31(31):3997-4013, 2013). Here we describe a HER2 FISH methodology to evaluate HER2 gene status in FFPE breast tumor specimens.

KEYWORDS:

Breast cancer; DNA probe; FISH; Fluorescence in situ hybridization; HER2; Herceptin; Human epidermal growth factor receptor 2; PathVysion

PMID:
26820945
DOI:
10.1007/978-1-4939-3444-7_5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center